

# NEVADA PEBP FY23

Eaton, Cynthia

CYNTHIA EATON ([CYNTHIA.EATON@EXPRESS-SCRIPTS.COM](mailto:CYNTHIA.EATON@EXPRESS-SCRIPTS.COM))

9/19/2023

Hello PEBP Team,

Attached you will find the FY23 summary files for the State of Nevada PEBP. I have highlighted the most impactful drivers of trend in the bullets below.

**Trend Summaries:**

**CDHP** – Plan Cost Net PMPM was \$70.51, which increased 3.9%. Utilization (+5.5%), Unit Cost (-2.0%) and Cost Share (+0.4%).

From an indication perspective, the most notable areas are as follows:

- **Inflammatory Conditions** – The plan’s top spend indication by Plan Cost Net. Plan Cost Net decreased \$1.1M (-20.1%) to \$4.5M. Patients declined from 308 to 279. Plan Cost Net PMPM decreased to \$13.57 (-3.6%).
  - *Humira (CF) Pen* – The leading Inflammatory Condition prescription by Plan Cost Net. Patient count decreased from 46 to 42. Adj. Rxs decreased to 325 from 319, with a reduction of \$41K (-2.4%) in Plan Cost Net.
  - *Stelara* – Ranked 2<sup>nd</sup> in spend by Plan Cost Net within Inflammatory Conditions. Patient count decreased from 13 to 10. Adj. Rxs decreased from 141 to 98 with decreased Plan Cost Net of \$331K (-50.1%).
  - *Tremfya* – Ranked 7<sup>th</sup> (previously ranked 3<sup>rd</sup>) in spend by Plan Cost Net within Inflammatory Conditions. Patients decreased from 13 to 11. Adj. Rxs decreased from 109 to 71, with a reduction of -\$271K (-60.7%) in Plan Cost Net.
- **HIV** – Ranked 4<sup>nd</sup> (previously 5<sup>th</sup>) in spend by Plan Cost Net. Plan Cost Net increased \$198k (+12.9%) to \$1.7M. Patients increased from 109 to 112. Plan Cost Net PMPM increased to \$5.23 (+36.2%).
  - *Biktarvy*- The leading HIV prescription by Plan Cost Net. Patient count increased from 15 to 21. Adj. Rxs increased from 134 to 168, with an increase of \$102K (24.8%) in Plan Cost Net.
  - *Apretude*- Ranked 8<sup>th</sup> in spend by Plan Cost Net within HIV. This is a newly utilized drug with a patient count of 6 and Adj. Rxs count of 28. Plan Cost Net for this period is \$61K.
  - *Prezista* – Ranked 10<sup>th</sup> in spend by Plan Cost Net within HIV. This is a newly utilized drug with a patient count of 1 and Adj. Rxs count of 11. Plan Cost Net for this period is \$22K.
- **Multiple Sclerosis** – Ranked 5<sup>th</sup> (previously 4<sup>th</sup>) in spend by Plan Cost Net. Plan Cost Net decreased \$671k (-43.8%) to \$860k. Patients decreased from 30 to 23. Plan Cost Net PMPM decreased to \$2.60 (-32.3%).
  - *Gilenya* – Ranked 2<sup>nd</sup> (previously ranked 1<sup>st</sup>) by Plan Cost Net within MS. Patients remained constant at 5. Adj. Rxs decreased from 53 to 26, with a reduction of \$99K (-36.9%) in Plan Cost Net.
  - *Dimethyl Fumarate* – Ranked 7<sup>th</sup> (previously 4<sup>th</sup>) in spend by Plan Cost Net within MS. Patients decreased from 6 to 2. Adj. Rxs decreased from 39 to 14, with a decrease of \$150K (-80.4%) in Plan Cost Net.

- *Tecfidera* – Ranked 9<sup>th</sup> (previously 2<sup>nd</sup>) by Plan Cost Net within MS. Patients decreased from 6 to 1. Adj. Rxs decreased from 38 to 6, with a decreased Plan Cost Net of \$220k (-86.2%).
- Peer Comparison: (ESI CDH Program) – CDHP PEBP continues to outperform their peer. Peer experienced Plan Cost Net PMPM of \$74.60 compared to PEBP’s Plan Cost Net PMPM of \$70.48. The Peer experienced a trend of 11.9%, while PEBP CDHP experienced a trend of 3.9%.

**EPO** – Plan Cost Net PMPM was \$153.72, which increased 14.3%. Utilization (+3.7%), Unit Cost (+10.2%), and Cost Share (+0.3%).

From an indication perspective, the most notable areas are as follows:

- **Endocrine Disorders** – Ranked 3<sup>rd</sup> (previously 4<sup>th</sup>) in indications by Plan Cost Net. Plan Cost Net increased \$566K (+88.1%) to \$1.2M. Patients increased from 35 to 37. Adj Rxs decreased from 232 to 227. Plan Cost Net PMPM increased to \$15.65 (+119.6%)
  - *Korlym* – The leading Endocrine Disorders prescription by Plan Cost Net. Patients increased from 1 to 2. Adj. Rxs increased from 8 to 17, with increased Plan Cost Net of \$566K (+100.5%)

Changes in other Endocrine Disorder drugs weren’t notable.

- **Inflammatory Conditions** – Leading indication in spend by Plan Cost Net. Plan Cost Net decreased \$281K (-10.4%) to \$2.4M. Patients decreased from 168 to 158. Plan Cost Net PMPM increased to \$31.36 (+4.6%).
  - *Humira(CF) Pen* – The leading Inflammatory Conditions prescription by Plan Cost Net. Patient count decreased from 27 to 26. Adj. Rxs increased from 231 to 240, with increased Plan Cost Net Cost of \$135K (+15.2%)
  - *Rinvoq* – Ranked 3<sup>rd</sup> (previously 8<sup>th</sup>) by Plan Cost Net. Patient count increased from 4 to 7. Adj. Rxs decreased from 30 to 54, with increased Plan Cost Net Cost of \$79K (+77.4%)
  - *Humira Pen* – Ranked 5<sup>th</sup> (previously 2<sup>nd</sup>) by Plan Cost Net. Patient count remained constant at 6. Adj. Rxs decreased from 71 to 32, with decreased Plan Cost Net Cost of \$168K (-57.9%)
- **Cancer** – Ranked 4<sup>th</sup> (previously 3<sup>rd</sup>) by Plan Cost Net. Plan Cost Net increased \$86K (11.6%) to \$827K. Patients decreased from 81 to 77. Plan Cost Net PMPM increased to \$10.71 (30.2%).
  - *Piqray*- The leading Cancer prescription by Plan Cost Net. Patient count remained constant at 1. Adj. Rxs increased from 12 to 13, with increased Plan Cost Net of \$30K (+15.2%).
  - *Mekinist* – Ranked 4<sup>th</sup> in spend for Cancer. This is a newly utilized drug with patient count of 1. Adj. Rxs count of 8, with Plan Cost Net of \$52K this period.
  - *Tafinlar* – Ranked 5<sup>th</sup> in spend for Cancer. This is a newly utilized drug with patient count of 1. Adj. Rxs count of 8, with Plan Cost Net of \$43K this period.

- **Skin Conditions** – Ranked 9<sup>th</sup> (previously 15<sup>th</sup>) by Plan Cost Net. Plan Cost Net increased \$78K (31.8%) to \$325k. Patients decreased from 652 to 570. Plan Cost Net PMPM increased to \$4.21 (+53.8%).
  - *Dupixent (Pen & Syringe Combined)* – The leading Skin Conditions prescription by Plan Cost Net. Patient count increased from 12 to 13. Adj. Rxs increased from 88 to 120, with increased Plan Cost Net of \$71K (+38.3%).
  - *Opzelura* – Ranked 3<sup>rd</sup> (previously 15<sup>th</sup>) in spend for Skin Conditions. Patients increased from 1 to 8. Adj. Rxs increased from 1 to 19, with an increase of \$23K (+1,574.4%) in Plan Cost Net.

Changes in other Skin Conditions drugs weren't notable.

- Peer Comparison (Government – West Region/SaveON) – This is a custom peer specifically created for PEBP. Population contains peers that are part of the Government – West region and have SaveOnSP in some or all of their plans. The Peer is outperforming PEBP. Peer has a Plan Cost Net PMPM of \$93.55 compared to PEBP's EPO Plan Cost Net PMPM of \$153.72. The Peer also experienced a lower trend of 6.9%, while PEBP's EPO Plan experienced trend of 14.3%.

**PPO** – Plan Cost Net PMPM was \$84.22, which increased 9.3%. Utilization (+4.4%), Unit Cost (+3.7%), and Cost Share (+1.2%).

From an indication perspective, the most notable areas are as follows:

- **Inflammatory Conditions** – Leading indication in spend by Plan Cost Net. Plan Cost Net increased \$1.4M (96.5%) to \$2.8M. Patient count increased from 113 to 201. Plan Cost Net PMPM increased to \$16.55 (+17%)
  - *Humira (CF) Pen* – The leading inflammatory condition prescription by Plan Cost Net. Patient count increased from 19 to 29. Adj Rxs increased from 125 to 233, with an additional \$408K (+86.7%) in Plan Cost Net.
  - *Stelara* – Ranked 3<sup>rd</sup> (previously ranked 6<sup>th</sup>) in spend for inflammatory conditions. Patient count increased from 3 to 9. Adj. Rxs increased from 29 to 82, with an additional \$190K (+217.6%) in Plan Cost Net.
  - *Skyrizi (Pen & Syringe Combined)* – Ranked 4<sup>th</sup> & 5<sup>th</sup> in spend for inflammatory conditions. Patient count increased from 4 to 14. Adj. Rxs increased from 26 to 116, with an additional \$262K (+354.7%) in Plan Cost Net.
- **Diabetes** – Ranked 2<sup>nd</sup> in spend by Plan Cost Net. Plan Cost Net increased \$992K (+106.3%) to \$1.9M. Patient count increased from 527 to 1045. Plan Cost Net PMPM increased to \$11.19(+22.7%)
  - *Ozempic* – The leading diabetes prescription by Plan Cost Net (previously ranked 2<sup>nd</sup>). Patient count increased from 58 to 206. Adj. Rxs increased from 413 to 1,278, with an additional \$338K (+196.2%) in Plan Cost Net.
  - *Trulicity* – Ranked 2<sup>nd</sup> (previously 1<sup>st</sup>) in spend by Plan Cost Net within Diabetes. Patient count increased from 58 to 100. Adj. Rxs increased from 586 to 867, with an additional \$134K (+60.5%) in Plan Cost Net.

- *Mounjaro* – Ranked 3rd in spend for diabetes. This is a newly utilized drug with patient count of 93. Adj. Rxs count of 424, with Plan Cost Net of \$189K this period.
- **Enzyme Deficiencies**– Ranked 6th (previously ranked 9th) in spend by Plan Cost Net. Plan Cost Net increased \$422K (+192.8%) to \$640k. Patient count increased from 2 to 4. Plan Cost Net PMPM increased to \$3.72 (+74.2%)
  - *Strensiq* – The leading Enzyme Deficiencies prescription by Plan Cost Net. Patient count remained constant at 1. Adj. Rxs increased from 1 to 11, with an additional \$216K (+162.9%) in Plan Cost Net.
  - *Nexviazyme*- Ranked 2nd in spend for Enzyme Deficiencies. This is a newly utilized drug with patient count of 1. Adj. Rxs count of 4, with Plan Cost Net of \$194K this period.

Changes in other Enzyme Deficiencies drugs weren't notable.

- Additional Notes: While not in the top 10 indications, PPO Plan saw new utilization of a very rare condition. Neuromyelitis Optica Spectrum, with one patient and Plan Cost Net of \$210k
- Peer Comparison (Government – West Region/SaveON) – This is a custom peer specifically created for PEBP. Population contains peers that are part of the Government – West region and have SaveOnSP in some or all of their plans. PEBP is outperforming the peer. Peer has a Plan Cost Net PMPM of \$93.55 compared to PEBP's EPO Plan Cost Net PMPM of \$84.21. However, the Peer experienced a lower trend of 6.9%, while PEBP's PPO Plan experienced trend of 9.3%.

**Total** – Overall, Plan Cost Net PMPM Trend is 7.6%. Trend is driven by increases almost exclusively on NonSpecialty. The NonSpecialty trend was driven by all three components of trend: utilization, unit cost and cost share. Specialty had an almost flat trend of 0.2%, which was mitigating to the overall trend. Utilization was driven by an increase in days per member, heavily weighted on NonSpecialty. Membership declined -1.9% vs. NonSpecialty days increased +2.1%. Member Cost Share Net % decrease was driven, at least in part, by COVID-19 impact test kits, which have no member cost share. Unit Cost increases were driven by utilization of more expensive brand drugs.

**Key Statistics:**

- Membership -1.9% (928 less members)
  - Members utilizing the benefit -2.4% (1,915 less patients)
- Total (Adj.Rxs) claims +0.8% (5,984 more Adj. Rxs)
- Gross Cost/Adj. Rx increased \$11.58 (+10.3%) to \$112.46
- Plan spend +\$9M (+14.5%)
- Rebates (estimated) increased \$6.4M (41.9%)
- Plan Cost Net PMPM (factoring rebates) increased \$6.05(+7.6%) to \$85.68
- Generic Fill Rate (GFR) increased 0.6 points to 85.9%
- Generic Fill Rate after excluding COVID-19 vaccines, test kits, and antivirals from both periods decreased 0.3 points to 88.1%

- Mail Penetration Rate (MPR) increased 4.8 points to 33.0%; factoring R90 Maintenance utilization, 90-day utilization rate grew from 60.2% to 61.6% this period, an increase of 1.4 percentage points.
- Member Cost Share Net % decreased 1.1 points, down to 25.8%.

*\*The data contained herein is pulled from a specific point-in-time and is subject to change at any time without notice due to a variety of factors, including but not limited to changes related to Member behavior, population demographics, system updates, and product availability. The data does not represent a guarantee and should not be used for audit purposes*